Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells

Barone BM, Elvidge AR: Ependymomas. A clinical survey. J Neurosurg 33: 428–438, 1970 Jellinger K, Scitelberger F: Zur Neuropathologie der Hirngeschwülste im Kindesalter. Wiener Medizinische Wochenschrift 120: 855–861, 1970 Schoenberg BS, Christine BW, Whisnant JP: The descriptive epidemiology of primary intracranial neoplasms-The Connecticut experience. Am J Epidemiol 104: 499–510, 1976 Küss R, Khoury S, Richard F, Fourcade F, Frantz P, Capelle JP: Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52: 29–33, 1980 Coulon RA, Till K: Intracranial ependymomas in children. A review of 43 cases. Child's Brain 3: 154–168, 1977 Russell DS, Rubinstein LJ: Pathology of tumours of the nervous system 5th ed. London: Edward-Arnold, 1989, pp 192–206 Salazar OM, Castro-Vita H, VanHoutte P, Rubin P, Aygun C: Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 59: 652–659, 1983 Nazar GB, Hoffman HJ, Becker LE, Jenkin D, Humphreys RP, Hendrick EB: Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 72: 408–417, 1990 Bloom HJG: Intracranial tumors: Response and resistance to therapeutic endeavors, 1970–1980. Int J Radiat Oncol Biol Phys 8: 1083–1113, 1982 Marks JE, Adler SJ: A comparative study of ependymomas by site of orgin. Int J Radiat Oncol Biol Phys 8: 37–43, 1982 Vanuytsel L, Brada M: The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 21: 825–830, 1991 Salazar OM, Rubin P, Bassano D, Marcial VA: Improved survival of patients with intracranial ependymomas by irradiation: Dose selection and field extension. Cancer 35: 1563–1573, 1975 Pendergrass TW, Milstein JM, Geyer JR, Mulne AF, Kosnik EJ, Morris JD, Heideman RL, Ruymann FB, Stuntz JT, Bleyer WA: Eight drugs in one day chemotherapy for brain tumours: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 5: 1221–1231, 1987 Levin VA, Edwards MSB, Gutin PH, Vestnys P, Fulton D, Seager M, Wilson CB: Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. J Neurosurg 61: 1063–1068, 1984 Sexauer CL, Khan A, Burger PC, Krischer JP, van Eys J, Vats T, Ragab AH: Cisplatin in recurrent pediatric brain tumors. Cancer 56: 1497–1501, 1985 Ragab AH, Burger P, Badnitsky S, Krischer J, van Eys J: PCNU in the treatment of recurrent medulloblastoma and ependymoma — a POG study. J Neuro-Oncol 3: 341–342, 1986 Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66, 1988 Piepmeier JM, Keefe DL, Weinstein MA, Yoshida D, Zielinski J, Lin TT, Chen Z, Naftolin F: Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 32: 422–429, 1993 von Schoultz E, Lundblad D, Bergh J, Grankvist K, Henriksson R: Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer 58: 326–329, 1988 von Schoultz E, Gunnarsson PO, Henriksson R: Uptake, metabolism and antiproliferative effect of estramustine phosphate in human glioma cell lines. Anti Cancer Res 9: 1713–1716, 1989 von Schoultz E, Lundgren E, Henriksson R: Effects of estramustine and its constituents on human malignant glioma cells. Anti Cancer Res 10: 693–696, 1990 Forsgren B, Björk P, Carlström K, Gustafsson J-Å, Pousette Å, Högberg B: Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivate of estradiol-17β. Proc Natl Acad Sci 76: 3149–3153, 1979 Björk P, Fritjofsson Å, Hartley-Asp B: Uptake and binding of estramustine and estromustine, metabolites of estramustine phosphate (Estracyt), in the human prostate, and new aspects on the cytotoxic activity of estramustine phosphatein vitro. In: Harzmann Ret al (eds) Experimentelle Urologie. Springer Verlag, Berlin, 1985, pp 341–353 Norlén BJ, Andersson S-B, Björk P, Gunnarsson PO, Fritjofsson Å: Uptake of estramustine phosphate (Estracyt) metabolites in prostatic cancer. J Urology 140: 1058–1062, 1988 von Schoultz E, Bergenheim T, Grankvist K, Henriksson R: Estramustine binding protein in human brain-tumor tissue. J Neurosurg 74: 962–964, 1991 Bergenheim AT, Gunnarsson PO, Edman K, von Schoultz E, Hariz MI, Henriksson R: Uptake and retention of estramustine and the presence of estramustine-binding protein in malignant brain tumors in humans. Br J Cancer 67: 358–361, 1993 Stearns ME, Wang M, Tew KD, Binder LI: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol 107: 2647–2656, 1988 Sheridan VR, Speicher LA, Tew KD: The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol 54: 268–276, 1991 Bjermer L, von Schoultz E, Norberg B, Henriksson R: Estramustine inhibits monocyte phagocytosis. The Prostate 13: 49–55, 1988 Kernohan JW, Sayre GP: Tumors of the central nervous system. Atlas of tumor pathology, Section X, fascicle 35, Armed Forces Institute of Pathology, Washington, 1952 Hsu SM, Raine L, Fanger H: Use of Avidin-Biotin-Peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580, 1981 Björk P: Expression of estramustine-binding protein (EMBP) in normal and neoplastic tissues. Doctorial Dissertation. Lund University, 1991 Bergh J, Björk P, Westlin J-E, Nilsson S: Expression of estramustine-binding associated protein in human lung cancer cell lines. Cancer Res 48: 4615–4619, 1988 Björk P, Borg Å, Fernö M, Nilsson S: Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma. Anti Cancer Res 113: 1173–1182, 1991 Friede RL, Pollak A: The cytogenetic basis for classifying ependymomas. J Neuropathol Exp Neurol 37: 103–118, 1978 Cruz-Sanchez FF, Rossi ML, Hughes JT, Cervos-Navarro J: An immunohistological study of 66 ependymomas. Histopathology 13: 443–454, 1988 Björk PA, Flücher SH, Nelde HJ: Estramustine-binding protein — a marker for effect of therapy in prostatic carcinoma? Scand J Urol Nephrol 107 (Suppl): 59–64, 1988 Flüchter SH, Nelde HJ, Björk P, Müntzing J, Bichler K-H: Effect of treatment on the expression of estramustine-binding protein EMBP in prostatic cancer patients: An immunohistochemical study. The Prostate 14: 27–43, 1989 Roessmann U, Velasco ME, Sindely SD, Gambetti P: Glial fibrillary acidic protein (GFAP) in ependymal cells during development. An immunocytochemical study. Brain Res 200: 13–21, 1980 Ludwin SK, Kosek JC, Eng LF: The topographical distribution of S-100 and GFA proteins in the adult rat brain: An immunohistochemical study using horseradish peroxidaselabelled antibodies. J Comp Neurol 165: 197–208, 1976 Sumi N, Yoshida H, Nakai K, Fujimoto S, Kameyama K, Nishiguchi Y, Tawaratani T, Yanagawa H, Nagasawa H, Enomoto H: Estramustine phosphate disodium (EMP). Oyo Yakuri 20: 757–802, 1980 Sumi N, Kameyama K, Nishiguchi Y, Fujimoto S, Tawaratani T, Nagasawa H, Enomoto H: Estramustine phosphate disodium (EMP). Oyo Yakuri 21: 549–586, 1981 Pierre-Kahn A, Hirsch JF, Roux FX, Renier D, Sainte-Rose C: Intracranial ependymomas in childhood. Survival and functional results of 47 cases. Child's Brain 10: 145–156, 1983